Veterinary Vaccines Market
Report Code
PH 3475
Published in
Jan, 2026, By MarketsandMarkets™
Veterinary Vaccines Market by Type (Porcine, Poultry, Bovine, Ruminant, Canine, Feline, Aquaculture), Technology (Live Attenuated, Inactivated, Toxoid, Recombinant), Route of Administration (Subcutaneous, Oral), End User - Global Forecast to 2031
$13.02B
MARKET SIZE, 2026
$18.46B
MARKET SIZE, 2031
7.2%
CAGR (2026-2031)
2026-2031
FORECAST PERIOD
VETERINARY VACCINES MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global veterinary vaccines market is projected to grow from USD 13.02 billion in 2026 to USD 18.46 billion by 2031, at a CAGR of 7.2% during the forecast period. The market was valued at USD 12.19 billion in 2025. Among the factors promoting the use of veterinary vaccines are increasing awareness of animal health, as well as the rising pet population and pet ownership. Examples of emerging trends affecting this market include government initiatives to improve animal health and the increased adoption of pet insurance. In developed markets such as North America and Europe, pet owners tend to insure their pets due to increased pet spending. Furthermore, the ongoing focus on developing novel, advanced vaccines, combined with their increasing use in emerging economies, is expected to drive market growth.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 12.19 Billion
Current Market Size (2026): USD 13.02 Billion
Forecast Market Size (2031): USD 18.46 Billion
CAGR (2026–2031): 7.2% -
SEGMENT LEADERSHIP:
Fastest-Growing Region: Asia Pacific is projected to be the fastest-growing market during the forecast period.
Type Leader: Livestock vaccines accounted for the largest share of 28.6% in 2025.
Disease Leader: Livestock diseases accounted for the largest share of 31.4% in 2025.
Route of Administration Leader: Intramuscular accounted for the largest market share.
Technology Leader: Live attenuated vaccines accounted for 43.4% of the veterinary vaccines market in 2025. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Leading companies include Zoetis, Merck & Co., Inc., and Boehringer Ingelheim International GmbH.
Emerging companies such as HIPRA, Hester Biosciences, and Vaxxinova have established strong positions through regional specialization, novel vaccine technologies, and expanding presence in emerging markets.
The veterinary vaccines market is poised for healthy growth in the years ahead, driven by rising awareness of animal health and increased demand for the prevention of zoonotic and livestock-related diseases. The growing demand for safe and effective vaccines to protect pets, poultry, and livestock is driven by the expansion of global meat and dairy consumption. Besides, biotechnology is improving with the discovery of recombinant and DNA-based vaccines, enhancing efficacy, safety, and production efficiency. The use of innovative delivery technologies and efficient cold-chain logistics is strengthening international access to vaccines. Such new developments contribute to the broader picture of preventive veterinary care and sustainable livestock management, positioning veterinary vaccines as a critical element in animal welfare and public health.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The veterinary vaccines market is undergoing a significant transformational wave due to evolving disease patterns. Advancements in vaccine technologies like combinations, vectors, and long-acting are creating an ease of administration and a wider coverage of protection. Meanwhile, the increasing biosecurity needs, tightening regulatory demands, and the perceived need for inexpensive, large-scale immunization in livestock shelters and operations have all shifted procurement and usage patterns. Digital health tools, better vaccination tracking, and extended distribution partnerships are further redefining how vaccines are delivered and monitored. In summary, the market is shifting from classical vaccines to more advanced, innovative, and cost-effective solutions for immunization.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Rise in companion animal population and pet ownership
-
Increasing incidence of infectious zoonotic diseases
RESTRAINTS
Impact
Level
Level
-
High cost of vaccine development
OPPORTUNITIES
Impact
Level
Level
-
Technological advancements for veterinary vaccine development
-
Untapped growth potential in emerging economies
CHALLENGES
Impact
Level
Level
-
Limited awareness about animal vaccines and shortage of trained veterinarians in low-income countries
-
Stringent regulatory requirements for licensing veterinary vaccines
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
VETERINARY VACCINES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Broad vaccine portfolio for livestock (avian influenza, bovine respiratory disease, swine fever) and pets (rabies, parvovirus) | Strong R&D in recombinant/vector vaccines | Improved livestock productivity, reduced outbreak losses, stronger food security, and enhanced pet health |
 |
Innovative platforms, including RNA-particle and recombinant vaccines | Targeting zoonotic diseases and production animals | Broader protection spectrum, longer shelf life, better safety profile |
 |
Poultry and swine vaccines, plus companion animal lines | Focus on global emerging disease threats | Reduced flock/herd mortality, improved farmer profitability, expanded vaccine access in developing regions |
 |
Expanding livestock and companion animal vaccines with scalable production capacity | Greater vaccine availability in emerging markets, better farmer incomes, and growth in preventive pet care |
 |
Companion animal vaccines with new formulations and delivery routes | Higher pet vaccination compliance, improved household disease prevention, and convenient administration |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The veterinary vaccines market ecosystem comprises a network of multinational key players, including Zoetis, Merck, Boehringer Ingelheim, Elanco, Virbac, and Ceva, as well as regional players such as Hester Biosciences. It integrates R&D and manufacturing hubs, government agencies driving mass immunization programs, veterinary clinics, and distributors ensuring last-mile delivery, and farmers/pet owners as end users. All these institutions rely on regulations established by governing authorities to ensure their safety and effectiveness, as well as on cold-chain logistics to maintain their quality. Additionally, they rely on research and academic institutions that further innovations for the next generation. End users include those in which these veterinary vaccines are adopted for final production.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Veterinary Vaccines Market, By Type
By type, the livestock vaccines segment is the largest in the animal vaccines market. Livestock animals are owned for the production of food such as meat or milk. With the increasing global population, demand for animal-derived food products is rising. This is leading to intensified livestock farming to fulfill these requirements. Overall, meat consumption is increasing due to improved production and rising demand, both domestically and globally. According to this report, the US was the world's largest beef producer in 2023, with over 30% of its farms used for beef production (Source: Carlisle Technology). As livestock farming becomes more industrialized and regulated, it will further increase the need for vaccines to prevent diseases.
Veterinary Vaccines Market, By Technology
The segment for live attenuated vaccines accounts for the major share of the veterinary vaccines market. Their ease of administration and long-term availability of immune responses are key drivers of this growth. They are highly effective and cost-efficient, providing protection against a range of serious diseases in livestock. Unsurprisingly, this increasing demand is in regions with highly intensive trade of healthy, disease-free livestock.
Veterinary Vaccines Market, By End User
In the veterinary vaccines market, the veterinary hospitals segment is the primary end user. Interior animal care has significantly improved in veterinary hospitals, which serve as primary care providers for the diagnosis and treatment of various healthcare conditions. Most veterinary vaccine manufacturers prefer to market their vaccines directly to licensed veterinarians or proprietary distributors that sell only to veterinarians rather than to third-party pharmacies. It attracts more veterinary professionals to veterinary hospitals, increases visits to veterinary clinics, and, through advocacy, raises awareness about animal health in developing and emerging countries. Increased spending on animal care has been another driving force behind the rise in hospital vaccinations for pets.
REGION
Asia Pacific to be fastest-growing region in global veterinary vaccines market during forecast period
The Asia Pacific veterinary vaccines market is projected to record the fastest growth during the forecast period. Countries like China and India are also seeing rising demand for veterinary care services, such as vaccinations, primarily due to increased pet ownership. The need for preventive healthcare, including vaccinations, is growing in animal health, whether for pets or production animals. With economic growth and rising disposable income in the region, demand for veterinary services and products will increase.
VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX
In the veterinary vaccines market, Zoetis (Star) leads with a strong global presence. It has a wide-ranging vaccine portfolio and advanced technologies, ensuring rapid acceptance among commercial farms and veterinary practices. Phibro Animal Health (Emerging Leader) is now on an accelerated path with innovative, cost-effective vaccine solutions. The company emphasizes emerging markets and the expansion of its footprint in animal health.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Zoetis (US)
- Merck & Co., Inc. (US)
- Boehringer Ingelheim International GmbH (Germany)
- Elanco (US)
- Virbac (France)
- Ceva (France)
- Phibro Animal Health Corporation (US)
- Hester Biosciences Limited (India)
- Neogen Corporation (US)
- HIPRA (Spain)
- Biogénesis Bagó (Argentina)
- Tianjin Ringpu Biotechnology Co., Ltd. (China)
- China Animal Husbandry Industry Co., Ltd. (China)
- Jinyu Bio-technology Co., Ltd. (China)
- Vaxxinova International B.V. (Netherlands)
- Endovac Animal Health (US)
- Brilliant Bio Pharma Pvt. Ltd. (India)
- Aptimmune Biologics, Inc. (US)
- Indian Immunologicals Ltd. (India)
- Torigen Pharmaceuticals, Inc. (US)
- Intas Pharmaceuticals Ltd. (India)
- Ourofino Animal Health (Brazil)
- Biovac Ltd. (Israel)
- Laboratoire LCV (France)
- Kyoritsu Seiyaku Corporation (Japan)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 12.19 Billion |
| Market Forecast in 2026 (Value) | USD 13.02 Billion |
| Market Forecast in 2031 (Value) | USD 18.46 Billion |
| Growth Rate | CAGR of 7.2% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Billion), Volume (Thousand Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America (US, Canada), Europe (Germany, France, UK, Italy, Spain, Netherlands, Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia Pacific), Latin America (Brazil, Mexico, Rest of Latin America), Middle East and Africa (GCC Countries, Rest of MEA) |
WHAT IS IN IT FOR YOU: VETERINARY VACCINES MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Detailed evaluation of veterinary vaccines by type (live attenuated, inactivated, recombinant, etc.), disease target (porcine, poultry, livestock, companion animals, aquaculture), and technology | Insights on market trends, emerging vaccine technologies, and efficacy comparisons to support informed decision-making |
| Company Information | Profiles of leading players, including Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, and Phibro, highlighting product portfolios, R&D pipelines, and market presence | Market positioning and competitive benchmarking to identify growth opportunities and strategic advantages |
| Geographic Analysis | Country-level veterinary vaccines demand mapping with a focus on APAC (ASEAN countries), Europe, and key emerging markets; evaluation of regional regulatory frameworks and adoption trends | Analysis of regional regulatory frameworks, vaccination adoption rates, and market access challenges |
RECENT DEVELOPMENTS
- November 2024 : Ceva Invested in a new vaccine manufacturing plant in Monor, Hungary. This development will establish a 7,000 m2 plant in Monor, equipped with the most advanced technologies, where Ceva will produce fermentation-based, multicomponent inactivated vaccines for animals, helping expand its global production capacity.
- November 2025 : Boehringer Ingelheim International GmbH launched the EURICAN L4 vaccine to protect dogs against the growing threat of leptospirosis, a severe and reemerging infectious disease.
- September 2024 : Merck & Co., Inc. announced the expansion of its NOBIVAC NXT platform with the launch of a groundbreaking new vaccine for Feline Leukemia Virus (FeLV). This vaccine is the first and only to incorporate RNA-Particle Technology, offering a novel alternative for preventing feline FeLV.
- March 2024 : Zoetis announced the purchase of a manufacturing site in Melbourne, Australia, to significantly expand its operations there and increase its future capabilities to develop and manufacture vaccines for sheep, cattle, dogs, cats, and horses.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
35
2
EXECUTIVE SUMMARY
40
3
PREMIUM INSIGHTS
45
4
MARKET OVERVIEW
Rising pet ownership and zoonotic disease awareness drive growth in veterinary vaccines market.
48
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
INCREASE IN COMPANION ANIMAL POPULATION AND PET OWNERSHIP
4.2.1.2
INCREASING INCIDENCE OF INFECTIOUS AND ZOONOTIC DISEASES
4.2.1.3
FAVORABLE INITIATIVES BY GOVERNMENT AGENCIES AND ANIMAL HEALTH ORGANIZATIONS
4.2.1.4
GROWING DEMAND FOR ANIMAL-DERIVED FOOD PRODUCTS
4.2.1.5
INCREASING PET INSURANCE PENETRATION AND ANIMAL HEALTH EXPENDITURE
4.2.2
RESTRAINTS
4.2.2.1
HIGH COST OF VETERINARY VACCINE DEVELOPMENT, MANUFACTURING, AND COLD-CHAIN DISTRIBUTION
4.2.3
OPPORTUNITIES
4.2.3.1
ADVANCEMENTS IN VACCINE TECHNOLOGIES AND STRATEGIC COLLABORATIONS
4.2.3.2
UNTAPPED OPPORTUNITIES IN EMERGING LIVESTOCK AND COMPANION ANIMAL MARKETS
4.2.4
CHALLENGES
4.2.4.1
LIMITED AWARENESS, TRAINING GAPS, AND SHORTAGE OF VETERINARY PROFESSIONALS IN LOW-INCOME COUNTRIES
4.2.4.2
STRINGENT REGULATORY PATHWAYS AND COMPLEX APPROVAL FRAMEWORKS
4.3
UNMET NEEDS & WHITE SPACES
4.3.1
UNMET NEEDS IN VETERINARY VACCINES MARKET
4.3.2
WHITE SPACE OPPORTUNITIES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1
INTERCONNECTED MARKETS
4.4.2
CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1
STRATEGIC MOVES IN VETERINARY VACCINES MARKET
5
INDUSTRY TRENDS
Navigate competitive pressures and pricing trends shaping the future of veterinary biologics.
63
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY
5.2.4
TRENDS IN GLOBAL VETERINARY BIOLOGICS INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.4
VALUE CHAIN ANALYSIS
5.5
ECOSYSTEM ANALYSIS
5.5.1
MANUFACTURERS
5.5.2
END USERS
5.5.3
REGULATORY BODIES
5.6
PRICING ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023–2025
5.6.2
AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023–2025
5.6.3
AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER, 2023–2025
5.6.4
AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY REGION, 2023–2025
5.7
TRADE ANALYSIS
5.7.1
IMPORT DATA (HS CODE 3002)
5.7.2
EXPORT DATA FOR (HS CODE 3002)
5.8
REIMBURSEMENT SCENARIO
5.9
KEY CONFERENCES & EVENTS, 2026–2027
5.10
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.11
INVESTMENT & FUNDING SCENARIO
5.12
CASE STUDY ANALYSIS
5.13
IMPACT OF 2025 US TARIFFS ON VETERINARY VACCINES MARKET
5.13.1
INTRODUCTION
5.13.2
KEY TARIFF RATES
5.13.3
PRICE IMPACT ANALYSIS
5.13.4
IMPACT ON COUNTRY/REGION
5.13.5
IMPACT ON END-USE SEGMENTS
5.13.5.1
VETERINARY HOSPITALS
5.13.5.2
VETERINARY CLINICS
5.13.5.3
OTHER END USERS (VETERINARY RESEARCH ORGANIZATIONS, GOVERNMENT VACCINATION CENTERS)
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize veterinary vaccines with precision, efficiency, and predictive disease management.
89
6.1
TECHNOLOGY ANALYSIS
6.1.1
KEY EMERGING TECHNOLOGIES
6.1.1.1
RECOMBINANT DNA TECHNOLOGY
6.1.1.2
MRNA-BASED VACCINES
6.1.2
COMPLEMENTARY TECHNOLOGIES
6.1.2.1
VACCINE ADJUVANT TECHNOLOGY
6.1.2.2
NEEDLE-FREE & MICRONEEDLE TECHNOLOGY
6.1.3
ADJACENT TECHNOLOGIES
6.1.3.1
GENOME EDITING TECHNOLOGY
6.2
TECHNOLOGY/PRODUCT ROADMAP
6.2.1
NEAR TERM (2025–2027)
6.2.2
MID TERM (2028–2030)
6.2.3
LONG TERM (2030+)
6.3
PATENT ANALYSIS
6.3.1
JURISDICTION & TOP APPLICANT ANALYSIS
6.4
FUTURE APPLICATIONS
6.4.1
AI-ENABLED & DATA-DRIVEN PROCEDURE OPTIMIZATION
6.4.2
PERSONALIZED & PRECISION VACCINATION
6.4.3
CONNECTED ANIMAL HEALTH ECOSYSTEMS & DIGITAL INTEGRATION
6.5
IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET
6.5.1
INTRODUCTION
6.5.2
MARKET POTENTIAL OF AI IN VETERINARY VACCINES
6.5.3
AI USE CASES
6.5.3.1
VACCINE DISCOVERY AND ANTIGEN IDENTIFICATION
6.5.3.2
DISEASE SURVEILLANCE AND OUTBREAK PREDICTION
6.5.3.3
VACCINE FORMULATION AND MANUFACTURING OPTIMIZATION
6.5.3.4
PRECISION VACCINATION AND HERD HEALTH MANAGEMENT
6.5.3.5
REGULATORY INTELLIGENCE AND SCIENTIFIC WORKFLOW AUTOMATION
6.5.4
KEY COMPANIES IMPLEMENTING AI
7
SUSTAINABILITY & REGULATORY LANDSCAPE
Unpack global sustainability regulations shaping eco-friendly veterinary vaccine materials and industry standards.
102
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY ANALYSIS
7.1.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2.1
NORTH AMERICA
7.1.2.2
EUROPE
7.1.2.3
REST OF THE WORLD
7.1.3
INDUSTRY STANDARDS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
RECYCLED & ECO-FRIENDLY MATERIALS FOR VETERINARY VACCINES
7.2.2
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.2.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlock profitability by understanding stakeholder influence and unmet needs in veterinary vaccine markets.
109
8.1
KEY STAKEHOLDERS & BUYING CRITERIA
8.1.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.1.2
BUYING CRITERIA
8.2
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2.1
DECISION-MAKING PROCESS
8.2.2
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.2.3
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.2.4
MARKET PROFITABILITY
9
VETERINARY VACCINES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million and Units | 28 Data Tables
115
9.1
INTRODUCTION
9.2
LIVESTOCK VACCINES
9.2.1
BOVINE VACCINES
9.2.1.1
INCREASING DEMAND FOR MEAT AND MILK TO DRIVE MARKET
9.2.1.2
GLOBAL VOLUME ANALYSIS OF BOVINE VACCINES, 2024–2031 (THOUSAND UNITS)
9.2.2
SMALL RUMINANT VACCINES
9.2.2.1
INCREASED LIVESTOCK POPULATION AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH
9.2.2.2
GLOBAL VOLUME ANALYSIS OF SMALL RUMINANT VACCINES, 2024–2031 (THOUSAND UNITS)
9.3
PORCINE VACCINES
9.3.1
GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH
9.3.1.1
GLOBAL VOLUME ANALYSIS OF PORCINE VACCINES, 2024–2031 (THOUSAND UNITS)
9.4
POULTRY VACCINES
9.4.1
HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH
9.4.1.1
GLOBAL VOLUME ANALYSIS OF POULTRY VACCINES, 2024–2031 (THOUSAND UNITS)
9.5
COMPANION ANIMAL VACCINES
9.5.1
CANINE VACCINES
9.5.1.1
INCREASING NUMBER OF PET DOGS AND GROWING PREVALENCE OF ZOONOTIC DISEASES TO SPUR MARKET GROWTH
9.5.1.2
GLOBAL VOLUME ANALYSIS OF CANINE VACCINES, 2024–2031(THOUSAND UNITS)
9.5.2
FELINE VACCINES
9.5.2.1
RISING ADOPTION OF CATS AND GROWING NEED FOR BETTER VETERINARY CARE TO BOOST MARKET GROWTH
9.5.2.2
GLOBAL VOLUME ANALYSIS OF FELINE VACCINES, 2024–2031 (THOUSAND UNITS)
9.6
AQUACULTURE VACCINES
9.6.1
INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH
9.6.1.1
GLOBAL VOLUME ANALYSIS OF AQUACULTURE VACCINES, 2024–2031 (THOUSAND UNITS)
9.7
OTHER VETERINARY VACCINES
10
VETERINARY VACCINES MARKET, BY DISEASE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 13 Data Tables
139
10.1
INTRODUCTION
10.2
LIVESTOCK DISEASES
10.2.1
BOVINE DISEASES
10.2.1.1
INCREASING GOVERNMENT SUPPORT TO AID THE MARKET GROWTH
10.2.2
SMALL RUMINANT DISEASES
10.2.2.1
GROWING RUMINANT VACCINES DEMAND TO PROPEL THE MARKET GROWTH
10.3
PORCINE DISEASES
10.3.1
PORCINE DISEASES TO ACCOUNT FOR LARGEST SHARE
10.4
POULTRY DISEASES
10.4.1
GROWING GOVERNMENT PROGRAMME TO CONTROL POULTRY DISEASES
10.5
COMPANION ANIMAL DISEASES
10.5.1
CANINE DISEASES
10.5.1.1
INNOVATIVE CANINE VACCINE DEVELOPMENT TO
10.5.2
FELINE DISEASES
10.5.2.1
FELINE DISEASE SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
10.6
AQUACULTURE DISEASES
10.6.1
GROWING FOCUS ON DEVELOPING AQUACULTURE VACCINES
10.7
OTHER DISEASES
11
VETERINARY VACCINES MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 6 Data Tables
153
11.1
INTRODUCTION
11.2
LIVE ATTENUATED VACCINES
11.2.1
EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH
11.3
INACTIVATED VACCINES
11.3.1
NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET
11.4
TOXOID VACCINES
11.4.1
TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS
11.5
RECOMBINANT VACCINES
11.5.1
BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION
11.6
OTHER VACCINE TECHNOLOGIES
12
VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 14 Data Tables
160
12.1
INTRODUCTION
12.2
SUBCUTANEOUS ROUTE OF ADMINISTRATION
12.2.1
EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH
12.3
INTRAMUSCULAR ROUTE OF ADMINISTRATION
12.3.1
BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH
12.4
ORAL ROUTE OF ADMINISTRATION
12.4.1
COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH
12.5
INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
12.5.1
COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION
12.6
INTRAOCULAR ROUTE OF ADMINISTRATION
12.6.1
SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH
12.7
OTHER ROUTES OF ADMINISTRATION
13
VETERINARY VACCINES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 4 Data Tables
175
13.1
INTRODUCTION
13.2
VETERINARY HOSPITALS
13.2.1
GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET
13.3
VETERINARY CLINICS
13.3.1
RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH
13.4
OTHER END USERS
14
VETERINARY VACCINES MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 18 Countries | 280 Data Tables.
181
14.1
INTRODUCTION
14.2
NORTH AMERICA
14.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
14.2.2
NORTH AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS)
14.2.3
US
14.2.3.1
US TO DOMINATE NORTH AMERICAN VETERINARY VACCINES MARKET DURING FORECAST PERIOD
14.2.4
CANADA
14.2.4.1
RISING PET OWNERSHIP AND INCREASING CHICKEN CONSUMPTION TO DRIVE DEMAND FOR VETERINARY VACCINES
14.3
EUROPE
14.3.1
EUROPE: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS)
14.3.2
MACROECONOMIC OUTLOOK FOR EUROPE
14.3.3
GERMANY
14.3.3.1
INCREASED POULTRY CONSUMPTION AND HIGH PET HEALTHCARE EXPENDITURE TO DRIVE MARKET
14.3.4
UK
14.3.4.1
RISING ADOPTION OF PETS TO AUGMENT MARKET GROWTH
14.3.5
FRANCE
14.3.5.1
RISING COMPANION ANIMAL AND LIVESTOCK POPULATION TO BOOST MARKET GROWTH
14.3.6
ITALY
14.3.6.1
BETTER AVAILABILITY OF PET PRODUCTS THROUGH LARGE-SCALE OUTLETS TO AUGMENT MARKET GROWTH
14.3.7
SPAIN
14.3.7.1
INCREASE IN VETERINARY PRACTICES AND WILLINGNESS TO SPEND ON ANIMAL HEALTHCARE TO DRIVE MARKET
14.3.8
NETHERLANDS
14.3.8.1
HIGH-DENSITY LIVESTOCK PRODUCTION AND STRONG BIOSECURITY STANDARDS TO DRIVE MARKET GROWTH
14.3.9
REST OF EUROPE
14.4
ASIA PACIFIC
14.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
14.4.2
ASIA PACIFIC: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS)
14.4.3
CHINA
14.4.3.1
INCREASING COMPANION ANIMAL POPULATION AND GROWING INCIDENCE OF ZOONOTIC DISEASES TO DRIVE MARKET
14.4.4
JAPAN
14.4.4.1
HIGH CONSUMPTION OF ANIMAL-DERIVED PRODUCTS AND INCREASED PET HEALTH EXPENDITURE TO PROPEL MARKET GROWTH
14.4.5
INDIA
14.4.5.1
GROWTH IN POULTRY INDUSTRY AND HIGH DEMAND FOR DAIRY PRODUCTS TO AUGMENT MARKET GROWTH
14.4.6
AUSTRALIA
14.4.6.1
INCREASE IN PER CAPITA INCOME AND RISE IN MEAT CONSUMPTION TO AID MARKET GROWTH
14.4.7
SOUTH KOREA
14.4.7.1
HIGH DEMAND FOR ANIMAL PROTEIN AND FAVORABLE GOVERNMENT SUBSIDIES FOR MEAT PRODUCTION TO SPUR MARKET GROWTH
14.4.8
REST OF ASIA PACIFIC
14.5
LATIN AMERICA
14.5.1
LATIN AMERICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS)
14.5.2
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
14.5.3
BRAZIL
14.5.3.1
WELL-ESTABLISHED LIVESTOCK INDUSTRY TO PROMOTE MARKET GROWTH
14.5.4
MEXICO
14.5.4.1
FOCUS ON PORK AND POULTRY MEAT PRODUCTION TO FUEL MARKET GROWTH
14.5.5
REST OF LATIN AMERICA
14.6
MIDDLE EAST & AFRICA
14.6.1
MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF VETERINARY VACCINES, BY TYPE, 2024–2031(THOUSAND UNITS)
14.6.2
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
14.6.3
GCC COUNTRIES
14.6.3.1
KINGDOM OF SAUDI ARABIA
14.6.3.1.1
FAVORABLE GOVERNMENT INITIATIVES FOR BETTER ANIMAL HEALTH INFRASTRUCTURE TO PROPEL MARKET GROWTH
14.6.3.2
UAE
14.6.3.2.1
FAVORABLE GOVERNMENT INITIATIVES TO SAFEGUARD NATIONAL LIVESTOCK POPULATION AND SUPPORT SUSTAINABLE AGRICULTURE
14.6.3.3
REST OF GCC COUNTRIES
14.6.4
REST OF MIDDLE EAST & AFRICA
15
COMPETITIVE LANDSCAPE
Discover strategic shifts and market dominance tactics of top veterinary vaccine players through 2025.
310
15.1
INTRODUCTION
15.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2024–2026
15.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY VACCINES MARKET
15.3
REVENUE ANALYSIS, 2023–2025
15.4
MARKET SHARE ANALYSIS, 2025
15.4.1
GLOBAL MARKET SHARE ANALYSIS (2025)
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1
STARS
15.5.2
EMERGING LEADERS
15.5.3
PERVASIVE PLAYERS
15.5.4
PARTICIPANTS
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1
COMPANY FOOTPRINT
15.5.5.2
TYPE FOOTPRINT
15.5.5.3
DISEASE FOOTPRINT
15.5.5.4
TECHNOLOGY FOOTPRINT
15.5.5.5
ROUTE OF ADMINISTRATION FOOTPRINT
15.5.5.6
REGION FOOTPRINT
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1
PROGRESSIVE COMPANIES
15.6.2
RESPONSIVE COMPANIES
15.6.3
DYNAMIC COMPANIES
15.6.4
STARTING BLOCKS
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.7
COMPANY VALUATION & FINANCIAL METRICS
15.7.1
FINANCIAL METRICS
15.7.2
COMPANY VALUATION
15.8
BRAND/PRODUCT COMPARISON
15.9
COMPETITIVE SCENARIO
15.9.1
PRODUCT LAUNCHES & APPROVALS
15.9.2
DEALS
15.9.3
EXPANSIONS
15.9.4
OTHER DEVELOPMENTS
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
333
16.1
KEY PLAYERS
16.1.1
MERCK & CO., INC.
16.1.1.1
BUSINESS OVERVIEW
16.1.1.2
PRODUCTS OFFERED
16.1.1.3
RECENT DEVELOPMENTS
16.1.1.3.1
PRODUCT LAUNCHES & APPROVALS
16.1.1.3.2
DEALS
16.1.1.3.3
EXPANSIONS
16.1.1.4
MNM VIEW
16.1.1.4.1
RIGHT TO WIN
16.1.1.4.2
STRATEGIC CHOICES
16.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
16.1.2
ZOETIS SERVICES LLC
16.1.3
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
16.1.4
ELANCO
16.1.5
VIRBAC
16.1.6
CEVA
16.1.7
PHIBRO ANIMAL HEALTH CORPORATION
16.1.8
HESTER BIOSCIENCES LIMITED
16.1.9
NEOGEN CORPORATION
16.1.10
HIPRA
16.1.11
BIOGÉNESIS BAGÓ
16.1.12
TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
16.1.13
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.
16.1.14
JINYU BIOTECHNOLOGY CO., LTD.
16.1.15
VAXXINOVA INTERNATIONAL B.V.
16.2
OTHER COMPANIES
16.2.1
ENDOVAC ANIMAL HEALTH REBRAND CA
16.2.2
BRILLIANT BIO PHARMA PRIVATE LIMITED
16.2.3
APTIMMUNE
16.2.4
INDIAN IMMUNOLOGICALS LTD.
16.2.5
TORIGEN
16.2.6
INTAS PHARMACEUTICALS LTD.
16.2.7
OUROFINO S.A
16.2.8
BIOVAC LTD.
16.2.9
LABORATOIRE LCV
16.2.10
KYORITSU SEIYAKU CORPORATION
17
RESEARCH METHODOLOGY
401
17.1
RESEARCH DATA
17.1.1
SECONDARY DATA
17.1.1.1
KEY DATA FROM SECONDARY SOURCES
17.1.2
PRIMARY DATA
17.1.2.1
KEY DATA FROM PRIMARY SOURCES
17.1.2.2
KEY INDUSTRY INSIGHTS
17.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
17.1.2.4
KEY INDUSTRY INSIGHTS
17.2
MARKET SIZE ESTIMATION
17.2.1
APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
17.2.2
APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
17.2.3
APPROACH 3: BOTTOM APPROACH
17.2.4
APPROACH 4: TOP-DOWN
17.2.5
BASE NUMBER CALCULATION
17.2.6
COMPANY PRESENTATIONS
17.2.7
PRIMARY INTERVIEWS
17.2.8
APPROACH 5: VOLUME ESTIMATION
17.2.9
APPROACH 6: DEMAND-SIDE
17.3
MARKET BREAKDOWN AND DATA TRIANGULATION
17.4
MARKET SHARE ASSESSMENT
17.5
RESEARCH ASSUMPTIONS
17.5.1
STUDY ASSUMPTIONS
17.5.2
GROWTH RATE ASSUMPTIONS
17.6
RISK ASSESSMENT
17.6.1
RESEARCH LIMITATIONS
18
APPENDIX
420
18.1
DISCUSSION GUIDE
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
18.4
RELATED REPORTS
18.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
STANDARD CURRENCY CONVERSION RATES
TABLE 2
GLOBAL MEAT MARKET INDICATORS, 2024 VS. 2025
TABLE 3
PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK (DEVELOPED VS. EMERGING MARKETS)
TABLE 4
ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
TABLE 5
ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
TABLE 6
KEY COST AND OPERATIONAL CHALLENGES ASSOCIATED WITH VACCINE DEVELOPMENT
TABLE 7
VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 8
GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION)
TABLE 9
LIST OF KEY VETERINARY VACCINE MANUFACTURERS
TABLE 10
LIST OF KEY END USERS
TABLE 11
LIST OF KEY REGULATORY BODIES
TABLE 12
AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2023–2025 (USD)
TABLE 13
AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY ROUTE OF ADMINISTRATION, 2023–2025 (USD)
TABLE 14
AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY END USER, 2023–2025 (USD)
TABLE 15
AVERAGE SELLING PRICE TREND OF CANINE VACCINES, BY REGION, 2023–2025 (USD)
TABLE 16
IMPORT DATA FOR HS CODE 3002-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 17
EXPORT DATA FOR HS CODE 3002-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 18
VETERINARY VACCINES MARKET: MAJOR CONFERENCES & EVENTS, 2026–2027
TABLE 19
BOVILIS NASALGEN-C: IMPROVED GROWTH PERFORMANCE AND REDUCED RESPIRATORY DISEASE IN VEAL CALVES
TABLE 20
UNISTRAIN PRRS: ENHANCED PRRS CONTROL AND REDUCED ANTIBIOTIC USAGE IN COMMERCIAL SWINE PRODUCTION
TABLE 21
FAO RABIES VACCINATION CASE STUDY
TABLE 22
RECIPROCAL TARIFF RATES ADJUSTED BY US, 2025
TABLE 23
KEY PRODUCT-RELATED TARIFF
TABLE 24
NORTH AMERICA: IMPACT OF US TARIFFS ON CANADA
TABLE 25
ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA
TABLE 26
EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK
TABLE 27
LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO
TABLE 28
VETERINARY VACCINES MARKET: KEY PATENTS, 2023–2025
TABLE 29
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 31
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 32
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES
TABLE 33
KEY BUYING CRITERIA FOR VETERINARY VACCINES, BY END USER
TABLE 34
VETERINARY VACCINES MARKET: ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 35
VETERINARY VACCINES MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
TABLE 36
VETERINARY VACCINES MARKET: KEY PROFITABILITY DRIVERS
TABLE 37
VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 38
LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 39
LIVESTOCK VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40
KEY PLAYERS PROVIDING BOVINE VACCINES
TABLE 41
BOVINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
BOVINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 43
KEY PLAYERS PROVIDING SMALL RUMINANT VACCINES
TABLE 44
SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45
SMALL RUMINANT VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 46
KEY PLAYERS PROVIDING PORCINE VACCINES
TABLE 47
PORCINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48
PORCINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 49
KEY PLAYERS PROVIDING POULTRY VACCINES
TABLE 50
POULTRY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
POULTRY VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 52
COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 53
COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
KEY PLAYERS PROVIDING CANINE VACCINES
TABLE 55
CANINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
CANINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 57
KEY PLAYERS PROVIDING FELINE VACCINES
TABLE 58
FELINE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
FELINE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 60
KEY PLAYERS PROVIDING AQUACULTURE VACCINES
TABLE 61
AQUACULTURE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62
AQUACULTURE VACCINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS)
TABLE 63
KEY PLAYERS PROVIDING OTHER COMMERCIAL VETERINARY VACCINES
TABLE 64
OTHER VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65
VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 66
LIVESTOCK VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 67
LIVESTOCK DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68
BOVINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69
SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70
PORCINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71
POULTRY DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72
COMPANION ANIMAL VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 73
COMPANION ANIMAL DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74
CANINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75
FELINE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76
AQUACULTURE DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77
OTHER DISEASES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 79
LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80
INACTIVATED VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81
TOXOID VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
RECOMBINANT VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83
OTHER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84
ROUTES OF ADMINISTRATION FOR MAJOR VETERINARY VACCINES, BY KEY PLAYER
TABLE 85
VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 86
COMMERCIALLY AVAILABLE VACCINES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION
TABLE 87
VETERINARY VACCINES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88
COMMERCIALLY AVAILABLE VACCINES WITH INTRAMUSCULAR ROUTE OF ADMINISTRATION
TABLE 89
VETERINARY VACCINES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90
COMMERCIALLY AVAILABLE VACCINES WITH ORAL ROUTE OF ADMINISTRATION
TABLE 91
VETERINARY VACCINES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92
COMMERCIALLY AVAILABLE VACCINES WITH INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
TABLE 93
VETERINARY VACCINES MARKET FOR INTRANASAL/SPRAY ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
COMMERCIALLY AVAILABLE VACCINES WITH INTRAOCULAR ROUTE OF ADMINISTRATION
TABLE 95
VETERINARY VACCINES MARKET FOR INTRAOCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96
COMMERCIALLY AVAILABLE VACCINES WITH OTHER ROUTES OF ADMINISTRATION
TABLE 97
VETERINARY VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98
VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 99
VETERINARY HOSPITALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
VETERINARY CLINICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101
OTHER END USERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102
VETERINARY VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 103
NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS)
TABLE 104
NORTH AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105
NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 106
NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 107
NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 108
NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 109
NORTH AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 110
NORTH AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111
NORTH AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 112
NORTH AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 113
NORTH AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 114
US: KEY MACROINDICATORS
TABLE 115
US: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 116
US: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117
US: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 118
US: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 119
US: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 120
US: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 121
US: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 122
US: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 123
US: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 124
CANADA: KEY MACROINDICATORS
TABLE 125
CANADA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 126
CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 127
CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128
CANADA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 129
CANADA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 130
CANADA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 131
CANADA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 132
CANADA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 133
CANADA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 134
EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS)
TABLE 135
EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136
EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 137
EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 138
EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 139
EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 140
EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141
EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142
EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 143
EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 144
EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 145
GERMANY: KEY MACROINDICATORS
TABLE 146
GERMANY: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147
GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 148
GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 149
GERMANY: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 150
GERMANY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 151
GERMANY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 152
GERMANY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 153
GERMANY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 154
GERMANY: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 155
UK: KEY MACROINDICATORS
TABLE 156
UK: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 157
UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 158
UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 159
UK: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 160
UK: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 161
UK: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 162
UK: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 163
UK: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 164
UK: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 165
FRANCE: KEY MACROINDICATORS
TABLE 166
FRANCE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 167
FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 168
FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 169
FRANCE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 170
FRANCE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171
FRANCE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172
FRANCE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 173
FRANCE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 174
FRANCE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 175
ITALY: KEY MACROINDICATORS
TABLE 176
ITALY: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177
ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178
ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 179
ITALY: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 180
ITALY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 181
ITALY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 182
ITALY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 183
ITALY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 184
ITALY: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 185
SPAIN: KEY MACROINDICATORS
TABLE 186
SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 187
SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 188
SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189
SPAIN: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 190
SPAIN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 191
SPAIN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 192
SPAIN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 193
SPAIN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 194
SPAIN: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 195
NETHERLANDS: KEY MACROINDICATORS
TABLE 196
NETHERLANDS: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 197
NETHERLANDS: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 198
NETHERLANDS: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 199
NETHERLANDS: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 200
NETHERLANDS: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201
NETHERLANDS: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202
NETHERLANDS: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 203
NETHERLANDS: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 204
NETHERLANDS: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 205
REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206
REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207
REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 208
REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 209
REST OF EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 210
REST OF EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 211
REST OF EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 212
REST OF EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 213
REST OF EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 214
ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS)
TABLE 215
ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216
ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 217
ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218
ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219
ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 220
ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 221
ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 222
ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 223
ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 224
ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 225
CHINA: KEY MACROINDICATORS
TABLE 226
CHINA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 227
CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 228
CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 229
CHINA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 230
CHINA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231
CHINA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 232
CHINA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 233
CHINA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 234
CHINA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 235
JAPAN: KEY MACROINDICATORS
TABLE 236
JAPAN: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237
JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238
JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 239
JAPAN: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 240
JAPAN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 241
JAPAN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 242
JAPAN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 243
JAPAN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 244
JAPAN: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 245
INDIA: KEY MACROINDICATORS
TABLE 246
INDIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 247
INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 248
INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 249
INDIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 250
INDIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 251
INDIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 252
INDIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 253
INDIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 254
INDIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 255
AUSTRALIA: KEY MACROINDICATORS
TABLE 256
AUSTRALIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 257
AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 258
AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 259
AUSTRALIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 260
AUSTRALIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 261
AUSTRALIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 262
AUSTRALIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 263
AUSTRALIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 264
AUSTRALIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 265
SOUTH KOREA: KEY MACROINDICATORS
TABLE 266
SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 267
SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 268
SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269
SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 270
SOUTH KOREA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 271
SOUTH KOREA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 272
SOUTH KOREA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 273
SOUTH KOREA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 274
SOUTH KOREA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 275
REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 276
REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 277
REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 278
REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 279
REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280
REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 281
REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 282
REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 283
REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 284
LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS)
TABLE 285
LATIN AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286
LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287
LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288
LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 289
LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 290
LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 291
LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 292
LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 293
LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 294
LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 295
BRAZIL: KEY MACROINDICATORS
TABLE 296
BRAZIL: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297
BRAZIL: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298
BRAZIL: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 299
BRAZIL: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 300
BRAZIL: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301
BRAZIL: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302
BRAZIL: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 303
BRAZIL: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 304
BRAZIL: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 305
MEXICO: KEY MACROINDICATORS
TABLE 306
MEXICO: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307
MEXICO: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 308
MEXICO: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 309
MEXICO: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 310
MEXICO: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 311
MEXICO: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312
MEXICO: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 313
MEXICO: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 314
MEXICO: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 315
REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316
REST OF LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 317
REST OF LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 318
REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 319
REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 320
REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321
REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 322
REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 323
REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 324
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031(THOUSAND UNITS)
TABLE 325
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 326
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 327
MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 328
MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 329
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 330
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 331
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 332
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 333
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 334
MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 335
GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 336
GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 337
GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 338
GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 339
GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 340
GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 341
GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 342
GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 343
GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 344
KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
TABLE 345
KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 346
KINGDOM OF SAUDI ARABIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 347
KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 348
KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 349
KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 350
KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 351
KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 352
KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 353
KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 354
UNITED ARAB EMIRATES: KEY MACROINDICATORS
TABLE 355
UAE: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 356
UAE: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 357
UAE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 358
UAE: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 359
UAE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 360
UAE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 361
UAE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 362
UAE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 363
UAE: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 364
REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 365
REST OF GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 366
REST OF GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 367
REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 368
REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 369
REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 370
REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 371
REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 372
REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 373
REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 374
REST OF MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 375
REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 376
REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2024–2031 (USD MILLION)
TABLE 377
REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 378
REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 379
REST OF MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 380
REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 381
REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 382
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY VACCINES MARKET, JANUARY 2023–MAY 2026
TABLE 383
VETERINARY VACCINES MARKET: DEGREE OF COMPETITION
TABLE 384
VETERINARY VACCINES MARKET: TYPE FOOTPRINT
TABLE 385
VETERINARY VACCINES MARKET: DISEASE FOOTPRINT
TABLE 386
VETERINARY VACCINES MARKET: TECHNOLOGY FOOTPRINT
TABLE 387
VETERINARY VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
TABLE 388
VETERINARY VACCINES MARKET: REGION FOOTPRINT
TABLE 389
VETERINARY VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 390
VETERINARY VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
TABLE 391
VETERINARY VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026
TABLE 392
VETERINARY VACCINES MARKET: DEALS, JANUARY 2023–MAY 2026
TABLE 393
VETERINARY VACCINES MARKET: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 394
VETERINARY VACCINES MARKET: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 395
MERCK & CO., INC.: COMPANY OVERVIEW
TABLE 396
MERCK & CO., INC.: PRODUCTS OFFERED
TABLE 397
MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023—MAY 2026
TABLE 398
MERCK & CO., INC.: DEALS, JANUARY 2023—MAY 2026
TABLE 399
MERCK & CO., INC.: EXPANSIONS, JANUARY 2023—MAY 2026
TABLE 400
ZOETIS SERVICES LLC: COMPANY OVERVIEW
TABLE 401
ZOETIS SERVICES LLC: PRODUCTS OFFERED
TABLE 402
ZOETIS SERVICES LLC: PRODUCT APPROVALS, JANUARY 2023—MAY 2026
TABLE 403
ZOETIS SERVICES LLC: DEALS, JANUARY 2023—MAY 2026
TABLE 404
ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2023−MAY 2026
TABLE 405
ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2023−MAY 2026
TABLE 406
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
TABLE 407
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
TABLE 408
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES, JANUARY 2023—MAY 2026
TABLE 409
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2023−MAY 2026
TABLE 410
ELANCO: COMPANY OVERVIEW
TABLE 411
ELANCO: PRODUCTS OFFERED
TABLE 412
ELANCO: PRODUCT APPROVALS JANUARY 2023—MAY 2026
TABLE 413
ELANCO: DEALS, JANUARY 2023–MAY 2026
TABLE 414
VIRBAC: COMPANY OVERVIEW
TABLE 415
VIRBAC: PRODUCTS OFFERED
TABLE 416
VIRBAC: PRODUCT LAUNCHES, JANUARY 2023—MAY 2026
TABLE 417
VIRBAC: DEALS, JANUARY 2023–MAY 2026
TABLE 418
VIRBAC: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 419
CEVA: COMPANY OVERVIEW
TABLE 420
CEVA: PRODUCTS OFFERED
TABLE 421
CEVA: PRODUCT LAUNCHES: JANUARY 2023—MAY 2026
TABLE 422
CEVA: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 423
PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW
TABLE 424
PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED
TABLE 425
HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW
TABLE 426
HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED
TABLE 427
HESTER BIOSCIENCES LIMITED: PRODUCT APPROVALS, JANUARY 2023—MAY 2026
TABLE 428
HESTER BIOSCIENCES LIMITED: DEALS, JANUARY 2023–MAY 2026
TABLE 429
NEOGEN CORPORATION: COMPANY OVERVIEW
TABLE 430
NEOGEN CORPORATION: PRODUCTS OFFERED
TABLE 431
NEOGEN CORPORATION: DEALS, JANUARY 2023–MAY 2026
TABLE 432
HIPRA: COMPANY OVERVIEW
TABLE 433
HIPRA: PRODUCTS OFFERED
TABLE 434
HIPRA: PRODUCT LAUNCHES, JANUARY 2023—MAY 2026
TABLE 435
HIPRA: DEALS, JANUARY 2023–MAY 2026
TABLE 436
BIOGÉNESIS BAGÓ: COMPANY OVERVIEW
TABLE 437
BIOGÉNESIS BAGÓ: PRODUCTS OFFERED
TABLE 438
BIOGÉNESIS BAGÓ: DEALS, JANUARY 2023–MAY 2026
TABLE 439
BIOGÉNESIS BAGÓ: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 440
TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 441
TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
TABLE 442
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: COMPANY OVERVIEW
TABLE 443
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: PRODUCTS OFFERED
TABLE 444
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026
TABLE 445
JINYU BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 446
JINYU BIOTECHNOLOGY CO., LTD.: PRODUCTS OFFERED
TABLE 447
JINYU BIOTECHNOLOGY CO., LTD.: PRODUCT APPROVALS, JANUARY 2023–MAY 2026
TABLE 448
VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW
TABLE 449
VAXXINOVA INTERNATIONAL B.V.: PRODUCTS OFFERED
TABLE 450
VAXXINOVA INTERNATIONAL B.V.: PRODUCT APPROVALS, JANUARY 2023–MAY 2026
TABLE 451
VAXXINOVA INTERNATIONAL B.V.: DEALS, JANUARY 2023–MAY 2026
TABLE 452
VAXXINOVA INTERNATIONAL B.V.: EXPANSIONS, JANUARY 2023–MAY 2026
TABLE 453
ENDOVAC ANIMAL HEALTH REBRAND CA: COMPANY OVERVIEW
TABLE 454
BRILLIANT BIO PHARMA PRIVATE LIMITED: COMPANY OVERVIEW
TABLE 455
APTIMMUNE: COMPANY OVERVIEW
TABLE 456
INDIAN IMMUNOLOGICALS LTD.: COMPANY OVERVIEW
TABLE 457
TORIGEN: COMPANY OVERVIEW
TABLE 458
INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
TABLE 459
OUROFINO S.A: COMPANY OVERVIEW
TABLE 460
BIOVAC LTD.: COMPANY OVERVIEW
TABLE 461
LABORATOIRE LCV.: COMPANY OVERVIEW
TABLE 462
KYORITSU SEIYAKU CORPORATION.: COMPANY OVERVIEW
TABLE 463
STUDY ASSUMPTIONS
TABLE 464
VETERINARY VACCINES MARKET: RISK ASSESSMENT ANALYSIS
LIST OF FIGURES
FIGURE 1
VETERINARY VACCINES MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
MARKET SCENARIO
FIGURE 3
GLOBAL VETERINARY VACCINES MARKET, 2024–2031
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS VETERINARY VACCINES MARKET, 2024–2026
FIGURE 5
DISRUPTIONS INFLUENCING GROWTH OF VETERINARY VACCINES MARKET
FIGURE 6
HIGH-GROWTH SEGMENTS IN VETERINARY VACCINES MARKET, 2026–2031
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN VETERINARY VACCINES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 8
RISING COMPANION ANIMAL OWNERSHIP TO DRIVE MARKET GROWTH
FIGURE 9
VETERINARY HOSPITALS SEGMENT IN ASIA PACIFIC REGION ACCOUNTED FOR LARGEST SHARE IN 2025
FIGURE 10
INDIA TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 11
VETERINARY VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 12
US: PET OWNERSHIP, BY TYPE, 2024–2025 (MILLION)
FIGURE 13
US: PET INDUSTRY EXPENDITURE, 2016–2025 (USD BILLION)
FIGURE 14
VETERINARY VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15
VETERINARY VACCINES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 16
VETERINARY VACCINES MARKET: VALUE CHAIN ANALYSIS
FIGURE 17
VETERINARY VACCINES MARKET ECOSYSTEM
FIGURE 18
AVERAGE SELLING PRICE OF VETERINARY VACCINES, BY KEY PLAYER, 2025 (USD)
FIGURE 19
AVERAGE SELLING PRICE OF CANINE VACCINES, BY REGION, 2025 (USD)
FIGURE 20
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 21
INVESTMENT & FUNDING SCENARIO
FIGURE 22
TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY VACCINES PATENTS, JANUARY 2015–MAY 2026
FIGURE 23
VETERINARY VACCINES MARKET: AI USE CASES
FIGURE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES
FIGURE 25
KEY BUYING CRITERIA FOR VETERINARY VACCINES, BY END USER
FIGURE 26
NORTH AMERICA: VETERINARY VACCINES MARKET SNAPSHOT
FIGURE 27
ASIA PACIFIC: VETERINARY VACCINES MARKET SNAPSHOT
FIGURE 28
REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY VACCINES MARKET, 2023–2025
FIGURE 29
GLOBAL MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY VACCINES MARKET, 2025
FIGURE 30
VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 31
VETERINARY VACCINES MARKET: COMPANY FOOTPRINT
FIGURE 32
VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 33
EV/EBITDA OF KEY VENDORS FOR VETERINARY VACCINES
FIGURE 34
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FOR VETERINARY VACCINES
FIGURE 35
VETERINARY VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 36
MERCK & CO., INC.: COMPANY SNAPSHOT (2025)
FIGURE 37
ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2025)
FIGURE 38
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025)
FIGURE 39
ELANCO: COMPANY SNAPSHOT (2025)
FIGURE 40
VIRBAC: COMPANY SNAPSHOT (2025)
FIGURE 41
PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 42
HESTER BIOSCIENCS LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 43
NEOGEN CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 44
TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45
VETERINARY VACCINE MARKET: RESEARCH DESIGN
FIGURE 46
PRIMARY SOURCES
FIGURE 47
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 48
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 49
BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS
FIGURE 50
RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 51
MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
FIGURE 52
REVENUE SHARE ANALYSIS ILLUSTRATION: MERCK & CO., INC. (2025)
FIGURE 53
BOTTOM-UP APPROACH
FIGURE 54
TOP-DOWN APPROACH
FIGURE 55
DEMAND-SIDE APPROACH
FIGURE 56
VETERINARY VACCINES MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031)
FIGURE 57
CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
FIGURE 58
MARKET DATA TRIANGULATION METHODOLOGY
Methodology
This study involved the extensive use of both primary and secondary sources. The research process involved examining various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape, fundamental market dynamics, and key players' strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, SEC filings of companies and publications from government sources such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), American Veterinary Medical Association (AVMA), Animal Health Institute (AHI), National Animal Health Laboratory Network (NAHLN), and Food and Agriculture Organization of the United Nations (FAO) were referred to identify and collect information for the global veterinary vaccines market study. It was also used to obtain important information about key players, market classification & segmentation according to industry trends, down to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and other key executives from various companies and organizations in the veterinary vaccines market. The primary sources from the demand side include hospitals & clinics, physiotherapy clinics, and home care settings. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
A breakdown of the primary respondents is provided below:
*C-level primaries include CEOs, CFOs, COOs, and VPs.
*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note: Companies are classified into tiers based on their total revenue. As of 2025, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
For the global market value, annual revenues were calculated using revenue mappings of major product manufacturers and OEMs active in the global veterinary vaccines market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 70-75% of the market share at the global level). Also, the global veterinary vaccines market was split into various segments and sub-segments based on:
- List of major players operating in the veterinary vaccines products market at the regional and/or country level
- Product mapping of various veterinary vaccine manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from veterinary vaccines (or the nearest reported business unit/product category)
- Revenue mapping of major players to cover at least 70-75% of the global market share as of 2025
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global point-of-care diagnostics market
The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
Market Size Estimation (Bottom Up approach & Top down approach)
Data Triangulation
After determining the overall size of the global veterinary vaccines market using the above-mentioned methodology, the market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, where applicable, to complete the overall market engineering process and derive the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
Market Definition
A veterinary vaccine is a biological preparation that provides immunity by stimulating an animal’s immune system to recognize and combat a specific pathogen. The veterinary vaccines market includes live attenuated, inactivated, recombinant, and toxoid vaccines for a wide range of animals, including poultry, livestock, porcine, aquaculture, and companion animals. Vaccination improves animal health, reduces the incidence of zoonotic diseases, supports higher productivity, and helps secure economic stability.
Stakeholders
- Animal vaccine manufacturers
- Animal healthcare product manufacturers
- Animal vaccine distributors and wholesalers
- Animal welfare associations
- Veterinary clinics and care centers
- Research and consulting firms
- Veterinary Research and Development Organizations
- Contract research organizations
- Contract manufacturing organizations
- Venture capitalists
Report Objectives
- To define, measure, and describe the global veterinary vaccines market by type, disease, technology, route of administration, and end user
- To provide detailed information about the major factors influencing the market growth (drivers, restraints, challenges, and opportunities)
- To strategically analyze the regulatory scenario, pricing, value chain analysis, supply chain analysis, ecosystem analysis, technology analysis, Porter’s Five Forces analysis, pipeline analysis, and patent analysis
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market segments in North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To strategically analyze the market structure, profile the key players in the global veterinary vaccines market, and comprehensively analyze their core competencies
- To track and analyze company developments such as acquisitions, partnerships, expansions, and product launches and approvals in the veterinary vaccines market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
- Further breakdown of the Rest of Europe veterinary vaccines market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the Rest of Asia Pacific veterinary vaccines market into Taiwan and others
- Further breakdown of the Rest of Latin America veterinary vaccines market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Southeast Asia veterinary vaccines market into Malaysia, Singapore, Australia, and others
COMPETITIVE LANDSCAPE ASSESSMENT
- Market share analysis, by region (North America and Europe), which provides market shares of the top 3-5 key players in the veterinary vaccines market
- Competitive leadership mapping for established players in the US
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Veterinary Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
- Canada Veterinary Vaccines Market
- US Veterinary Vaccines Market
- Germany Veterinary Vaccines Market
- UK Veterinary Vaccines Market
- France Veterinary Vaccines Market
- Italy Veterinary Vaccines Market
- Spain Veterinary Vaccines Market
- Netherlands Veterinary Vaccines Market
- China Veterinary Vaccines Market
- Japan Veterinary Vaccines Market
- India Veterinary Vaccines Market
- Australia Veterinary Vaccines Market
- South Korea Veterinary Vaccines Market
- New Zealand Veterinary Vaccines Market
- Brazil Veterinary Vaccines Market
- Mexico Veterinary Vaccines Market
- UAE Veterinary Vaccines Market
Growth opportunities and latent adjacency in Veterinary Vaccines Market
Marlo
Jun, 2026
I went through the Veterinary Vaccines Market report to evaluate demand patterns across companion and livestock segments to refine our portfolio prioritization in animal health vaccines..
Cassian
Jun, 2026
I used the Veterinary Vaccines Market insights to better understand evolving vaccine technologies and disease burden trends impacting immunization strategies in veterinary practice..
Wren
Jun, 2026
I filled the form after reviewing the Veterinary Vaccines Market analysis to gauge long-term investment potential in preventive animal healthcare and regional expansion opportunities..